Alfonsus Johannes Maria van den Eertwegh

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 436 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Sander Kelderman, Bianca Heemskerk, Harm van Tinteren et al. · Cancer Immunology Immunotherapy · 2014 · 300 citations · Full text

Medicine, Cancer Biology, Oncology +15

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · NEJM Evidence · 2022 · 150 citations

Pharmacy, Oncology, Pharmacotherapy +17